AAPL 171.24 +2.63 (+1.56%)MSFT 110.63 +1.88 (+1.73%)FB 146.64 +4.56 (+3.21%)ZNGA 3.8 +0.15 (+3.97%)NVDA 152.46 +4.29 (+2.89%)WBA 83.03 +1.21 (+1.48%)GOOG 1080.15 +28.57 (+2.72%)PIH 5 -0.12 (-2.34%)
AAPL 171.24 +2.63 (+1.56%)MSFT 110.63 +1.88 (+1.73%)FB 146.64 +4.56 (+3.21%)ZNGA 3.8 +0.15 (+3.97%)NVDA 152.46 +4.29 (+2.89%)WBA 83.03 +1.21 (+1.48%)GOOG 1080.15 +28.57 (+2.72%)PIH 5 -0.12 (-2.34%)

Balance Sheet ACAD Quote ACADIA Phar

All | Income Statement | Balance Sheet | Cash Flow | Retained Earnings | PPE Schedule | Intangible and Goodwill Schedule
Year 201420152016
CashAndCashEqui 102 164 69
ShortTermInvest 113 365 272
Cash 215 529 341
AccountReceivab 2 6 17
Inventories 0 4 5
DeferredIncomeT 0 0 0
OtherCurrentAss 0 1 10
TotalCurrentAss 219 548 373
PPE 5 6 7
AccumulatedDepr -3 -3 -4
NetPPE 2 3 3
EquityAndOtherI 0 0 0
Goodwill 0 0 0
IntangibleAsset 0 7 6
OtherLTAssets 1 3 3
TotalNonCurrent 3 13 11
TotalAssets 222 561 385
ShortTermDebt 0 0 0
AccountsPayable 2 4 9
TaxesPayable 0 0 0
AccruedLiabilit 20 36 40
DeferredRevenue 0 3 0
OtherCurrentLia 0 0 0
TotalCurrentLia 22 43 49
Debt 0 0 0
DeferredTaxesLi 0 0 0
DeferredRevenue 0 0 0
OtherLTLiabilit 0 0 0
TotalNonCurrent 0 0 0
TotalLiabilitie 22 43 49
CommonStock 0 0 0
AdditionalPaidI 862 1,452 1,559
RetainedEarning -663 -934 -1,224
AccumulatedOthe 0 0 0
TotalStockholde 200 518 335
TotalLiabilitie 222 561 385
ACADIA Pharmaceuticals Inc. income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes ACADIA Pharmaceuticals Inc. FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.